Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Herceptin Market?

The market size for herceptin has notably expanded in the past few years. It is projected to increase from $7.10 billion in 2024 to $7.55 billion in 2025, representing a compound annual growth rate (CAGR) of 6.4%. The growth observed in the historic period is due to factors such as regulatory approvals, escalations in breast cancer incidences, advancements in monoclonal antibody technology, positive results from clinical trials, and the rise in healthcare spending.

What Growth Rate Is Forecasted for the Herceptin Market by 2029?

Expectations are high for robust growth in the Herceptin market over the next several years, with predictions reaching $9.59 billion in 2029 and demonstrating a compound annual growth rate of 6.1%. Several factors are contributing to this expected growth in the forecasted period, such as the proliferation of biosimilars, the increasing implementation of targeted therapies, enhanced access to healthcare in developing markets, progressive R&D in the field of oncology and an escalation in the rate of HER2-positive cancer cases. The predicted trends for this period include the production of antibody-drug conjugates, advancements in biosimilar compounds, incorporation of AI in the discovery of new drugs, approaches focusing on personalized medicine, and enhancements in drug delivery systems.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24236&type=smp

Which Key Companies Are Shaping the Future of the Herceptin Market?

Major companies operating in the herceptin market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Genentech Inc., Dr. Reddy’s Laboratories, Celltrion Healthcare, Mundipharma, Biocon Limited, Bio-Techne Corporation, Samsung Bioepis Co Ltd, AryoGen Pharmed, InvivoGen, Abnova Corporation, Shanghai Henlius Biotech Inc., Prestige Biopharma Pte Ltd.

Which Factors Are Driving Demand in the Herceptin Industry?

The surge in breast cancer cases is anticipated to stimulate the expansion of the herceptin market in the future. Breast cancer, a cancer that originates in the breast cells, typically in the milk ducts or lobules, encompasses invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The escalation in breast cancer can be attributed in part to alterations in lifestyle, such as heightened alcohol intake, inadequate diet, and absence of physical activity, all of which contribute to an elevated risk. With the diagnosis of more individuals with breast cancer, especially HER2-positive instances, the need for powerful targeted treatments like herceptin is steadily increasing. For example, as per the American Cancer Society, a cancer organization based in the US, around 319,750 new breast cancer cases are forecasted for January 2025, and roughly 42,680 fatalities are predicted due to the disease. Consequently, the rising prevalence of breast cancer is facilitating the growth of the herceptin market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24236&type=smp

How Is the Herceptin Market Segmented by Several Divisions?

The herceptin market covered in this report is segmented –

1) By Product: Biologic, Biosimilar

2) By Application: Breast Cancer, Gastric Cancer

3) By Payer: Commercial And Private, Public

4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy

Subsegments:

1) By Biologic: Intravenous (IV) Biologics, Subcutaneous (SC) Biologic

2) By Biosimilar: Intravenous (IV) Biosimilars, Subcutaneous (SC) Biosimilars

What are the Emerging Market Trends Driving the Growth of the Herceptin Industry?

Key players in the herceptin market are advancing new treatment pathways, including groundbreaking biosimilar products, to boost patient accessibility and augment therapeutic results for HER2-positive cancers. Groundbreaking biosimilar products, which are almost identical substitutes of certified biologic drugs, are created using cutting-edge biotechnology to guarantee comparable safety, efficacy, and quality. For example, in April 2024, Accord BioPharma Inc., an American pharmaceutical company, gained approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a herceptin (trastuzumab) biosimilar, for the treatment of HER2-overexpressing breast and gastric cancers. Biosimilars like HERCESSI exhibit similar efficacy and safety to their reference biologics while possibly providing more economical treatment alternatives.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/herceptin-global-market-report

Which Regions Are Driving Growth in the Herceptin Market?

North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herceptin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24236&type=smp

This Report Delivers Insight On:

1. How big is the herceptin market, and how is it changing globally?

2. Who are the major companies in the herceptin market, and how are they performing?

3. What are the key opportunities and risks in the herceptin market right now?

4. Which products or customer segments are growing the most in the herceptin market?

5. What factors are helping or slowing down the growth of the herceptin market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model